These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 27461240)

  • 41. Local induction of bladder Th1 responses to combat urinary tract infections.
    Wu J; Bao C; Reinhardt RL; Abraham SN
    Proc Natl Acad Sci U S A; 2021 Mar; 118(10):. PubMed ID: 33653961
    [TBL] [Abstract][Full Text] [Related]  

  • 42. d-Mannose Treatment neither Affects Uropathogenic
    Scribano D; Sarshar M; Prezioso C; Lucarelli M; Angeloni A; Zagaglia C; Palamara AT; Ambrosi C
    Molecules; 2020 Jan; 25(2):. PubMed ID: 31941080
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of Intranasal Outer Membrane Vesicles with Cholera Toxin and Injected MF59C.1 as Adjuvants for Malaria Transmission Blocking Antigens AnAPN1 and Pfs48/45.
    Pritsch M; Ben-Khaled N; Chaloupka M; Kobold S; Berens-Riha N; Peter A; Liegl G; Schubert S; Hoelscher M; Löscher T; Wieser A
    J Immunol Res; 2016; 2016():3576028. PubMed ID: 27239480
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Systemic immunization with conserved pilus-associated adhesins protects against mucosal infections.
    Palaszynski S; Pinkner J; Leath S; Barren P; Auguste CG; Burlein J; Hultgren S; Langermann S
    Dev Biol Stand; 1998; 92():117-22. PubMed ID: 9554264
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Protection against genital tract Chlamydia trachomatis infection following intranasal immunization with a novel recombinant MOMP VS2/4 antigen.
    Hadad R; Marks E; Kalbina I; Schön K; Unemo M; Lycke N; Strid Å; Andersson S
    APMIS; 2016 Dec; 124(12):1078-1086. PubMed ID: 27859689
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Responses to the soluble flagellar protein FliC are Th2, while those to FliC on Salmonella are Th1.
    Cunningham AF; Khan M; Ball J; Toellner KM; Serre K; Mohr E; MacLennan IC
    Eur J Immunol; 2004 Nov; 34(11):2986-95. PubMed ID: 15384042
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Enhanced effect of BCG vaccine against pulmonary Mycobacterium tuberculosis infection in mice with lung Th17 response to mycobacterial heparin-binding hemagglutinin adhesin antigen.
    Fukui M; Shinjo K; Umemura M; Shigeno S; Harakuni T; Arakawa T; Matsuzaki G
    Microbiol Immunol; 2015 Dec; 59(12):735-43. PubMed ID: 26577130
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn's disease.
    Mydock-McGrane LK; Hannan TJ; Janetka JW
    Expert Opin Drug Discov; 2017 Jul; 12(7):711-731. PubMed ID: 28506090
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A recombinant P4 protein of Haemophilus influenzae induces specific immune responses biologically active against nasopharyngeal colonization in mice after intranasal immunization.
    Hotomi M; Ikeda Y; Suzumoto M; Yamauchi K; Green BA; Zlotnick G; Billal DS; Shimada J; Fujihara K; Yamanaka N
    Vaccine; 2005 Jan; 23(10):1294-300. PubMed ID: 15652672
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The FimH Gene in Uropathogenic Escherichia coli Strains Isolated From Patients With Urinary Tract Infection.
    Hojati Z; Zamanzad B; Hashemzadeh M; Molaie R; Gholipour A
    Jundishapur J Microbiol; 2015 Feb; 8(2):e17520. PubMed ID: 25825648
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Luteolin decreases the attachment, invasion and cytotoxicity of UPEC in bladder epithelial cells and inhibits UPEC biofilm formation.
    Shen XF; Ren LB; Teng Y; Zheng S; Yang XL; Guo XJ; Wang XY; Sha KH; Li N; Xu GY; Tian HW; Wang XY; Liu XK; Li J; Huang N
    Food Chem Toxicol; 2014 Oct; 72():204-11. PubMed ID: 25051393
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier, and adjuvant.
    Holmgren J; Czerkinsky C; Lycke N; Svennerholm AM
    Am J Trop Med Hyg; 1994; 50(5 Suppl):42-54. PubMed ID: 8203723
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice.
    McCluskie MJ; Davis HL
    J Immunol; 1998 Nov; 161(9):4463-6. PubMed ID: 9794366
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The catalytic A1 domains of cholera toxin and heat-labile enterotoxin are potent DNA adjuvants that evoke mixed Th1/Th17 cellular immune responses.
    Bagley K; Xu R; Ota-Setlik A; Egan M; Schwartz J; Fouts T
    Hum Vaccin Immunother; 2015; 11(9):2228-40. PubMed ID: 26042527
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In silico design of fusion protein of FimH from uropathogenic Escherichia coli and MrpH from Proteus mirabilis against urinary tract infections.
    Habibi M; Asadi Karam MR; Bouzari S
    Adv Biomed Res; 2015; 4():217. PubMed ID: 26605246
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A proposal for safety standards for human use of cholera toxin (or Escherichia coli heat-labile enterotoxin) derivatives as an adjuvant of nasal inactivated influenza vaccine.
    Tamura SI; Kurata T
    Jpn J Infect Dis; 2000 Jun; 53(3):98-106. PubMed ID: 10957706
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A flow cytometry-based assay for screening FimH antagonists.
    Scharenberg M; Abgottspon D; Cicek E; Jiang X; Schwardt O; Rabbani S; Ernst B
    Assay Drug Dev Technol; 2011 Oct; 9(5):455-64. PubMed ID: 21675870
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Partial protection against chlamydial reproductive tract infection by a recombinant major outer membrane protein/CpG/cholera toxin intranasal vaccine in the guinea pig Chlamydia caviae model.
    Andrew DW; Hafner LM; Beagley KW; Timms P
    J Reprod Immunol; 2011 Sep; 91(1-2):9-16. PubMed ID: 21856018
    [TBL] [Abstract][Full Text] [Related]  

  • 59. FimH antagonists: bioisosteres to improve the in vitro and in vivo PK/PD profile.
    Kleeb S; Pang L; Mayer K; Eris D; Sigl A; Preston RC; Zihlmann P; Sharpe T; Jakob RP; Abgottspon D; Hutter AS; Scharenberg M; Jiang X; Navarra G; Rabbani S; Smiesko M; Lüdin N; Bezençon J; Schwardt O; Maier T; Ernst B
    J Med Chem; 2015 Mar; 58(5):2221-39. PubMed ID: 25666045
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of intranasal IL-12 to target predominantly Th1 responses to nasal and Th2 responses to oral vaccines given with cholera toxin.
    Marinaro M; Boyaka PN; Jackson RJ; Finkelman FD; Kiyono H; Jirillo E; McGhee JR
    J Immunol; 1999 Jan; 162(1):114-21. PubMed ID: 9886376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.